Why India is shifting its pharma export focus from US
India is shifting gears on where it sends its medicines, aiming to depend less on the US (which still buys over a third of Indian pharma exports—about $10.5 billion in FY25).
With recent trade tensions in the mix, India's now looking at new markets like Africa, Latin America, Southeast Asia, Russia, Brazil, and the Netherlands.
There's also a push to sell more finished drugs to China.
What does this mean for India?
This move isn't just about business—it's about playing it smart.
By spreading out where its medicines go, India can dodge risks from US tariffs and tough regulations.
Plus, tapping into emerging markets could mean 20% more exports and help shrink India's big trade gap with China (which supplies over 60% of India's pharma raw materials).
All this helps keep billions in export revenue safe and keeps India strong as one of the world's top drug producers.